GLP-1

Tirzepatide vs Semaglutide: The Complete 2026 Comparison Guide

Medici

27 Apr 2026 — 6 min read

Two injectable medications now dominate the weight-loss conversation: semaglutide (sold as Ozempic for diabetes and Wegovy for obesity) and tirzepatide (Mounjaro for diabetes, Zepbound for obesity). Both belong to the GLP-1 class, both require once-weekly injections, and both have transformed how clinicians approach obesity management. But they are not the same drug — and the differences matter when you or your prescriber are deciding which one is right for you.

This guide breaks down the science, the clinical trial data, the side-effect profiles, the dosing schedules, and the practical considerations you need to make an informed decision.

How Each Drug Works: Mechanisms of Action

Semaglutide — Pure GLP-1 Agonist

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. GLP-1 is a gut hormone released after you eat. It tells the pancreas to release insulin, slows stomach emptying, and sends satiety signals to the brain. By mimicking this hormone with a long-acting synthetic analogue, semaglutide reduces appetite, lowers blood glucose, and produces sustained weight loss.

Semaglutide binds the GLP-1 receptor with high affinity and has a plasma half-life of approximately 7 days, enabling once-weekly dosing. It was the first GLP-1 agonist to demonstrate major cardiovascular risk reduction in large outcome trials.

Tirzepatide — Dual GIP/GLP-1 Agonist

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor co-agonist — a single molecule that activates two distinct hormonal pathways. This is the key pharmacological difference.

GIP receptors are distributed differently than GLP-1 receptors — they appear at high density in adipose tissue and in brain regions involved in energy homeostasis. Because the two pathways act on overlapping but distinct targets, their effects are additive rather than redundant. Tirzepatide has been described as an "imbalanced" agonist: it binds the GIP receptor (Ki = 0.135 nM) with affinity similar to native GIP, while its GLP-1 receptor affinity (Ki = 4.23 nM) is approximately five-fold weaker than native GLP-1, yet it still produces robust GLP-1 pathway activity.

The result is a drug that appears to leverage synergistic hormonal signalling — more appetite suppression, greater insulin sensitisation, and enhanced fat mobilisation compared to pure GLP-1 agonism alone. Tirzepatide's half-life is approximately 5 days, slightly shorter than semaglutide, but still sufficient for once-weekly injection.

Head-to-Head Efficacy: What the Trials Show

SURMOUNT-5: The Landmark Comparison

For years, comparisons between the two drugs relied on indirect analyses — network meta-analyses and observational data. That changed with the SURMOUNT-5 trial, published in the New England Journal of Medicine in 2025, which directly compared tirzepatide and semaglutide in adults with obesity but without type 2 diabetes over 72 weeks.

The results were decisive:

Tirzepatide participants lost an average of 20.2% of body weight (~50 lbs)
Semaglutide participants lost an average of 13.7% of body weight (~33 lbs)
Nearly 32% of tirzepatide users achieved ≥25% body weight reduction, vs. 16% on semaglutide
Tirzepatide also produced greater reductions in waist circumference

Meta-Analyses Confirm the Pattern

A 2025 systematic review and meta-analysis incorporating both randomised controlled trials and real-world data (28,980 participants across seven studies) found tirzepatide was significantly superior for weight loss: mean difference of 4.23% greater weight reduction (95% CI: 3.22–5.25%, P < 0.01). The advantage was dose- and duration-dependent — at doses above 10 mg, the mean difference grew to 6.50% (95% CI: 5.93–7.08%).

For type 2 diabetes outcomes, tirzepatide also outperforms semaglutide on HbA1c reduction in most head-to-head studies, though both produce clinically meaningful glycaemic control.

Dosing Schedules

Semaglutide (Wegovy / Ozempic)

Both Ozempic (diabetes) and Wegovy (obesity) are injected subcutaneously once weekly. Wegovy follows a 16-week titration:

Weeks 1–4: 0.25 mg/week
Weeks 5–8: 0.5 mg/week
Weeks 9–12: 1.0 mg/week
Weeks 13–16: 1.7 mg/week
Week 17+: 2.4 mg/week (maintenance)

Ozempic for diabetes tops out at 2.0 mg/week (or 0.5–1.0 mg/week at lower maintenance doses, depending on glycaemic targets).

Tirzepatide (Zepbound / Mounjaro)

Tirzepatide uses a slower, 4-week step-up titration, with increments of 2.5 mg:

Weeks 1–4: 2.5 mg/week
Weeks 5–8: 5 mg/week
Weeks 9–12: 7.5 mg/week
Weeks 13–16: 10 mg/week
Weeks 17–20: 12.5 mg/week
Week 21+: 15 mg/week (maximum dose)

Maintenance doses of 5, 10, or 15 mg are available; many patients achieve their weight-loss goals at 10 mg and do not need the maximum dose.

Important note on switching: There is no direct dose conversion between semaglutide and tirzepatide. Patients switching between the drugs should restart titration from the lowest dose, regardless of their previous maintenance dose.

Side Effects: What to Expect

Both drugs share a similar gastrointestinal side-effect profile, because both slow gastric emptying. In real-world community surveys (analysis of over 410,000 posts), users self-reported the following:

Nausea: ~37% of users
Fatigue: ~17%
Vomiting: ~16%
Constipation: ~15%
Diarrhoea: ~13%

These effects are most common during dose escalation and typically resolve as the body adapts. Staying well-hydrated, eating smaller meals, and avoiding high-fat or spicy foods during titration helps most patients tolerate the drugs well.

Less Common but Serious Risks

Both semaglutide and tirzepatide carry black-box warnings regarding:

Thyroid C-cell tumours (based on rodent studies; human relevance unknown — contraindicated in patients with personal/family history of medullary thyroid carcinoma or MEN2)
Pancreatitis (discontinue if suspected)
Hypoglycaemia (especially when used with insulin or sulfonylureas)
Gallbladder disease (rapid weight loss increases gallstone risk)

Muscle Loss Considerations

A notable concern with both drugs is lean mass loss during rapid weight reduction. Studies suggest approximately 25–40% of weight lost on GLP-1 agonists may come from lean tissue, not fat. Resistance training and adequate protein intake (1.2–1.6 g/kg bodyweight) are strongly recommended while on either medication.

Cardiovascular Benefits

This is a meaningful area of divergence between the two drugs — not because tirzepatide lacks cardiovascular benefit, but because the evidence base is more mature for semaglutide.

Semaglutide's Cardiovascular Record

Semaglutide (Wegovy) has FDA approval to reduce cardiovascular risk — specifically the risk of heart attack, stroke, and cardiovascular death — in adults with established cardiovascular disease who are overweight or obese. The SELECT trial (2023) demonstrated a ~20% reduction in major adverse cardiovascular events. This level of regulatory approval and trial evidence is currently unique to semaglutide in this class.

Tirzepatide's Emerging Data

Cardiovascular outcome trials for tirzepatide are underway (the SURPASS-CVOT programme), and preliminary data are encouraging — tirzepatide improves blood pressure, lipids, and metabolic markers more aggressively than semaglutide at equivalent doses. Final CVOT results are anticipated in the coming years. Until then, tirzepatide does not carry the same FDA cardiovascular risk-reduction indication as semaglutide.

Compounding Pharmacy Availability (2026)

The compounding landscape for both drugs has shifted significantly:

Compounded tirzepatide: Largely unavailable. Tirzepatide was removed from the FDA drug shortage list in October 2024. Under current FDA policy, 503A and 503B compounders may no longer routinely compound tirzepatide, as shortage-based exemptions no longer apply.
Compounded semaglutide: Also restricted but in a different phase. The FDA enforcement discretion period for compounded semaglutide injections ended March 10, 2025. However, compounded semaglutide products using the base (non-salt) form remain more widely available through certain compounders, and remain the most cost-accessible GLP-1 option. Patients should verify their compounding pharmacy's compliance status carefully.

Brand-name pricing remains a significant barrier: Wegovy and Ozempic typically list above $1,000/month without insurance; Zepbound and Mounjaro are similarly priced. Insurance coverage — including Medicare for Wegovy under cardiovascular indications — has expanded but remains inconsistent.

Who Should Choose Which Drug?

The right choice depends on your clinical situation, goals, and prescriber's judgment. Here are the key differentiators:

Consider semaglutide if: you have established cardiovascular disease and want proven CV risk reduction; your insurance covers it but not tirzepatide; or you experienced intolerable side effects on tirzepatide.

Consider tirzepatide if: you want maximum weight-loss efficacy; you have type 2 diabetes with high HbA1c that needs aggressive lowering; you have significant insulin resistance or metabolic syndrome; or semaglutide did not produce adequate results.

The Bottom Line

When it comes to raw weight-loss power, tirzepatide's dual GIP/GLP-1 mechanism gives it a meaningful edge — roughly 6–7 additional percentage points of body weight lost in head-to-head trials, and dramatically higher rates of ≥25% weight loss. For cardiovascular risk reduction, semaglutide's established trial record and FDA indication make it the stronger choice in patients with pre-existing heart disease.

Both drugs represent a paradigm shift in the treatment of obesity and metabolic disease. The best medication is the one your prescriber recommends based on your full clinical picture, your goals, and your body's response to treatment.

This article is for educational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before starting, stopping, or changing any medication.